Oncology Clinical Trials is a department of Intermountain Cancer Services that is committed to improving the care and treatment for patients who are diagnosed with cancer by offering cancer research studies as an option to standard therapies. 

Study Summary List



  • N0577: Phase III Intergroup Study of  Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma. | NCT00887146 (DCP-001 Required with this Trial)


  • NRG BN003: A Phase III, Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma. | NCT03180268  ***Open in UCR***


Node positive

  • A011202(Temporarily closed to accrual pending amendment approval) 
  • A221505: A Phase III Randomized Trial Of Hypofractionated Post Mastectomy Radiation With Breast Reconstruction. | NCT03414970 (DCP-001 Required With This Trial)
  • NSABP B-51: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy | NCT01872975  (DCP-001 Required with this Trial)

Triple negative

  • NRG BR003: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer | NCT02488967 (DCP-001 Required with this Trial) 
  • ROCHE ImPassion: A Phase III Multicenter, Randomized, Open-Label Study Comparing Atezolizumab (Anti-PD-L1 Antibody) in Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone in Patients with Operable Triple Negative Breast Cancer Atezoluzumab is provided. | ***Open at IMC and Dixie*** NCT03498716



  • TEG Study: (Temporary closed due to funding) 
  • A021502: Randomized Trial Of Standard Chemotherapy Alone Or Combined With Atezolizumab As Adjuvant Therapy For Patients With Stage III Colon Cancer And Deficient DNA Mismatch Repair  Atezolizumab is provided | NCT02912559 (DCP-001 Required With This Trial)ed. 
  • Colocare: (Temporarily on hold) An international prospective cohort study of stage I-IV colorectal cancer patients. | NCT02328677 ***Open at LDS and IMC***


  • NRG GI002: (Temporarily closed before activation of another experimental arm)  



  • NRG GU002: Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel | NCT03070886
  • NRG GU005: Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer. | NCT03367702 (DCP-001 Required With This Trial)


  • NRG-GY005: A Randomized Phase II/III study of the combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone, or Standard of care chemotherapy in women with recurrent platinum-resistant or –refractory ovarian, fallopian tube, or primary peritoneal cancer (COCOS) Olaparib and cediranib provided. | NCT024502266 **Open at IMC and Dixie**


  • GOG 0263: Phase III Randomized Study of Adjuvant Radiation Versus Chemoradiation Therapy in Patients With Intermediate-Risk Stage I-IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy. | NCT01101451  (DCP-001 Required with this Trial)
  • RTOG 0724: A Phase III Randomized Study of Concurrent Chemotherapy and Pelvic RADIATION THERAPY With or Without Adjuvant Chemotherapy in High-Risk Patients with Early- stage Cervical Carcinoma Following Radical Hysterectomy | NCT00980954 (DCP-001 Required with this Trial)


  • SAVE: Short Course Adjuvant Vaginal Cuff Brachytherapy (VCB) in Early Endometrial Cancer Compared to Standard of Care ***Open at LDS and IMC***


  • RTOG 1008: A Randomized Phase II Study of Adjuvant Concurrent Radiation and Chemotherapy versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors | NCT01220583 
  • NRG HN001: Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA) | NCT02135042
  • RTOG 1216(Temporarily closed due to phase II accrual being met) 



  • Astellas 2215-CL-0201: a Phase 2/3 Multicenter, Open-Label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients not Eligible for Intensive Induction Chemotherapy | ASP2215 Provided NCT02752035 **Open at LDS Hospital Only**
  • BMT CTN 1506 / Astellas 2215-CL-0304 (MORPHO): A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FLT3/ITD AML | Gilteritinib/Placebo Provided ***Open at LDS Only*** NCT02997202
  • Alliance A041501: A Phase III, Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL. | Inotuzumab Ozogamicin is provided.  ***Open at LDS Only*** NCT03150693 


Non-Small Cell

  • A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) A screening trial for A081105, E4512, and EA5142 | NCT02194738 (DCP-001 Required with this Trial)
  • A081105: Randomized Study Of Erlotinib Or Placebo In Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC) (An ALCHEMIST Treatment Trial) | Erlotinib provided. NCT02193282 (DCP-001 Required with this Trial)
  • E4512:   A Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein (An ALCHEMIST Treatment Trial) | Crizotinib provided. NCT02201992 (DCP-001 Required with this Trial)
  • STABLE-MATES: A Randomized Phase III Study of Sublobar Resection (SR) versus Stereotactic Ablative Radiotherapy (SAbR) in High Risk Patients with Stage I Non-Small Cell Lung Cancer (NSCLC) – The STABLE-MATES Trial | *** Open at IMC Only *** NCT02468024


  • A051301 A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma of the Activated B-cell Subtype | Ibrutinib/placebo provided. NCT02443077 **Open at LDS Hospital Only** (DCP-001 Required with this trial)


  • JUNO (Celgene) Outreach 017007: A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-Cell Non Hodgkin Lymphoma (NHL) in the Outpatient Setting | Lisocabtagene Maraleucel, Fludarabine, Cyclophosphamide is provided. NCT03744676 
  • JUNO Transcend 017006: A Phase II Study of Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy in Adult Patients with Aggressive B-Cell NHL | Lisocabtagene Maraleucel, Fludarabine, Cyclophosphamide is provided. NCT03483103 


  • SWOG S1512: A Phase II and Pilot Trial of PD-1 Blockade with MK-3475 (Pembrolizumab) in Patients with Resectable or Unresectable Desmoplastic Melanoma (DM) | MK-3475 (Pembrolizumab) is provided. NCT02775851 
  • POLYNOMA(Temporarily Closed to Accrual)
  • AMGEN REGISTRY: A Registry Study to Evaluate the Survival and Long-Term Safety of Subjects With Melanoma Who Previously Received Talimogene Laherparepvec | ***Open at IMC Only*** NCT02173171
  • AMGEN Imlygic: A Postmarketing Prospective Cohort Study of Melanoma Patients Treated With IMLYGIC in Clinical Practice to Characterize the Risk of Herpetic Infection Among Patients, Close Contacts, and Health Care Providers; and Long-term Safety in Treated Patients. | ***Open at IMC Only*** NCT02910557
  • SWOG S1616: A Phase II Randomized Study of Nivolumab (NSC-748726) with Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD-1 or Anti-PD-L1 Agent. | Ipilimumab, Nivolumab provided NCT003033576 


  • TAPUR Study: The Targeted Agent and Profiling Utilization Registry (TAPUR) Study | *** Open at IMC, Dixie and Cedar City *** NCT02693535
  • NRG CC004: Phase II double blind dose finding trial of bupropion versus placebo for sexual desire in women with breast or gynecologic cancer. | Bupropion provided. NCT03180294 (DCP-001 Required with this Trial)
  • Merck-002: A Phase 2 Study of Olaparib Monotherapy in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer | Olaparib is provided.  NCT03742895 ***Open at Dixie***
  • Replimune (RP1): An Open-Label, Multicenter, Phase I/II Study of RP1 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors – Protocol RPL-001-16 | RP1 and Nivolumab are provided.  ***Open at Dixie and IMC*** NCT03767348


  • RTOG 1216: (Temporarily closed due to phase II accrual being met) Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered with Concurrent Cisplatin versus Docetaxel versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck | NCT01810913
  • POLYNOMA (Temporarily closed to accrual)A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence | Dr. Hyngstrom & Dr. Bowles Only. Part A of Study Enrollment is closed to accrual. Part B and Open Label Extension are open to enrollment. NCT01546571 
  • NRG GI002: (Temporarily closed before activation of another experimental arm) A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer | Pembrolizumab provided. NCT02921256 
  • A011202: (Temporarily closed to accrual pending amendment approval) A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (CT1-3 N1) Who Have Positive Sentinel Lymph Node Disease after Neoadjuvant Chemotherapy | NCT01901094 (DCP-001 Required with this Trial)
  • NRG GU006:(Temporarily closed to Step 1 accrual) Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer. | Apalutamide provided. NCT03371719 


  • SWOG S1802: A Phase III Randomized Trial of Standard Systemic Therapy (SST) versus Standard Systemic Therapy plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer. | NCT03678025 
  • RTOG 3506:  A Randomized Phase II Trial of Salvage Radiotherapy with Standard vs Enhanced Androgen Deprivation Therapy (with Enzalutamide) in Patients with Post-Prostatectomy PSA Recurrences with Aggressive Disease Features | Enzalutamide provided NCT03809000
  • Bayer ON-TRK: Prostpective non-interventional study in patients with locally advanced or metastatic TRK fusion cancer treated with larotrectinib. | ***Open at Dixie and IMC***  NCT04142437